Management ChangeJul 6, 2026, 09:22 AM
Vicore Pharma Appoints Rob Slack as Chief Scientific Officer
AI Summary
Vicore Pharma Holding AB announced the appointment of Rob Slack, PhD, FRSB, as its new Chief Scientific Officer, effective July 6, 2026. Dr. Slack brings over two decades of leadership in drug discovery, particularly in respiratory biology and fibrosis, having previously held senior roles at GSK and Galecto. He will lead the company's research strategy and pipeline development, succeeding Johan Raud, MD, PhD, who will transition to a Senior Advisor role.
Key Highlights
- Vicore Pharma appointed Rob Slack, PhD, FRSB, as its new Chief Scientific Officer.
- Dr. Slack brings over 20 years of experience in fibrosis and respiratory translational science.
- He previously served as Vice President and Head of Respiratory Biology at GSK.
- Dr. Slack also acted as Chief Scientific Officer at Galecto.
- He helped deliver multiple approved respiratory medicines, including vilanterol and umeclidinium.
- Dr. Slack succeeds Johan Raud, MD, PhD, who will transition to Senior Advisor.
- He will lead Vicore's research strategy and development of its AT2 receptor agonist pipeline.
Price Impact